INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - Dyne Therapeutics ( NASDAQ:DYN )
NEW YORK, Aug. 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ( "Dyne" or the "Company" ) DYN. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy ( DMD )
- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early ...
Does Dyne Therapeutics ( DYN ) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?
The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss - Dyne Therapeutics ( NASDAQ:DYN )
Dyne Therapeutics Inc DYN reported a loss for the second quarter on Monday. The company posted a quarterly loss of 97 cents per share, which met the analyst consensus estimate.
Dyne Reports Wider Loss in Fiscal Q2
Dyne Therapeutics ( NASDAQ:DYN ) , a biopharmaceutical company focused on advancing therapies for serious muscle diseases, released its results for the second quarter of fiscal 2025 on July 28, 2025. In the release, Dyne reported a net loss per share of $ ( 0.97 ) ( GAAP ) , missing analyst ...
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned commercial launch in early ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - Dyne Therapeutics ( NASDAQ:DYN )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ( "Dyne" or the "Company" ) DYN. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - Dyne Therapeutics ( NASDAQ:DYN )
NEW YORK, July 06, 2025 ( GLOBE NEWSWIRE ) -- NEW YORK, June 30, 2025 ( GLOBENEWSWIRE ) Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ( "Dyne" or the "Company" ) DYN. Such investors are advised to contact Danielle Peyton at [email protected] or ...
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - AeroVironment ( NASDAQ:AVAV ) , Dyne Therapeutics ( NASDAQ:DYN )
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Tesla, Inc. TSLA fell sharply in pre-market trading after CEO Elon Musk reignited political comeback rumors following his criticism of President Donald Trump's spending bill.
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Argo Blockchain ( NASDAQ:ARBK ) , Applied DNA Sciences ( NASDAQ:APDN )
Shares of Thumzup Media Corporation TZUP rose sharply in today's pre-market trading after the company announced a $6.5 million registered direct offering. Thumzup Media shares jumped 20.4% to $8.45 in the pre-market trading session. Here are some other stocks moving in pre-market trading.
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
WALTHAM, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. ( Nasdaq: DYN ) , a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of ...
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock - Dyne Therapeutics ( NASDAQ:DYN )
WALTHAM, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. DYN, a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 ...
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. ( Nasdaq: DYN ) , a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public ...
Dyne Therapeutics Announces Proposed Public Offering of Common Stock - Dyne Therapeutics ( NASDAQ:DYN )
WALTHAM, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. DYN, a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of ...
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital - Dyne Therapeutics ( NASDAQ:DYN ) , Hercules Capital ( NYSE:HTGC )
- $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points - WALTHAM, Mass., June 30, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Dyne Therapeutics, Inc. - DYN - Dyne Therapeutics ( NASDAQ:DYN )
NEW YORK, June 23, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ( "Dyne" or the "Company" ) DYN. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Why Is Dyne Therapeutics Stock Trading Lower On Tuesday? - Dyne Therapeutics ( NASDAQ:DYN )
DYNE-101 improved myotonia by 3.3 seconds at 6 months; gains sustained through 12 months across multiple measures. Accelerated approval filing shifted to late 2026; Phase 3 trial expected to start in Q1 2026. Live on Wednesday June 18: 3 Summer "Power Patterns" Are About to Trigger ( One With ...
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting - Dyne Therapeutics ( NASDAQ:DYN )
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 -
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET - Dyne Therapeutics ( NASDAQ:DYN )
WALTHAM, Mass., June 16, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
WALTHAM, Mass., June 16, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. ( Nasdaq: DYN ) , a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an ...
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
- DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model ...
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - Dyne Therapeutics ( NASDAQ:DYN )
- FDA ( CDER ) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 initiated to support potential submission for U.S.
Crescent Biopharma Appoints David Lubner to Board of Directors - GlycoMimetics ( NASDAQ:GLYC )
Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments - Dyne Therapeutics ( NASDAQ:DYN )
- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, Mass., April 15, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
WALTHAM, Mass., April 14, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. ( Nasdaq: DYN ) , a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity ...
Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Booz Allen Hamilton ( NYSE:BAH ) , Betterware de Mexico SAPI ( NYSE:BWMX )
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Friday. Shares of Booz Allen Hamilton Holding Corporation BAH fell sharply in today's pre-market trading. Goldman Sachs analyst Noah Poponak downgraded Booz Allen Hamilton from Buy to Neutral and lowered the ...
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - GlycoMimetics ( NASDAQ:GLYC )
Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D., Appointed Chief Medical Officer Additional Leadership Appointments: Rick Scalzo, MBA, as Chief Financial Officer, and Amy Reilly, as Chief Communications Officer
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path - Dyne Therapeutics ( NASDAQ:DYN )
Dyne Therapeutics plans a global Registrational Expansion Cohort for DYNE-101, aiming for U.S. Accelerated Approval in H1 2026. JP Morgan lowered Dyne's price target from $18 to $17, citing concerns over regulatory clarity and the lack of recent data updates.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) to Newly Appointed Chief Financial Officer
WALTHAM, Mass., March 20, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. ( Nasdaq: DYN ) , a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to ...
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - Dyne Therapeutics ( NASDAQ:DYN )
- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
- Continued favorable safety profile for ...
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
BMO forecasts DYNE-101 peak global sales of $4.3 billion by 2035. Dyne plans to start a Registrational Expansion Cohort in H1 2026 for potential accelerated approval. Find out which stock just plummeted to the bottom of the new Benzinga Rankings. Updated daily-spot the biggest red flags before ...
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum - Dyne Therapeutics ( NASDAQ:DYN )
WALTHAM, Mass., March 11, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
WALTHAM, Mass., March 11, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. ( Nasdaq: DYN ) , a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to ...
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- Received FDA Fast Track Designation for DYNE-101 in ...
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
- Data from DELIVER and ACHIEVE Clinicals Trial to be Presented ...
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference - Dyne Therapeutics ( NASDAQ:DYN )
- Data from DELIVER and ACHIEVE Clinicals Trial to be Presented - - Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on the Use of Splicing Correction as a Prognostic Biomarker of Functional Outcomes in DM1 -
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics ( DYN )
Dyne Therapeutics (DYN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near ...
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
WALTHAM, Mass., Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. ( Nasdaq: DYN ) , a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is ...
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Dyne Therapeutics ( NASDAQ:DYN )
WALTHAM, Mass., Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
Corcept, Amneal, Dyne, Nektar and Cardiol have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics ( DYN ) Looks Ripe for a Turnaround
Dyne Therapeutics (DYN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near ...
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- Company Anticipates Submitting for U.S. Accelerated Approval in ...
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday? - Dyne Therapeutics ( NASDAQ:DYN )
At 6.8 mg/kg Q8W, DYNE-101 showed significant splicing correction and functional improvement at 3 and 6 months. Dyne aims for U.S. Accelerated Approval in H1 2026, supported by biomarker and functional data. Get 5 New Stock Recommendations Every Week On Friday, Dyne Therapeutics, Inc.
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 ( DM1 ) ; Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 - Dyne Therapeutics ( NASDAQ:DYN )
- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements. potential to support H1 2026 submission for U.S.
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 ( DM1 ) ; Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026
- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements. potential to support H1 2026 submission for U.S.
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Dyne Therapeutics ( NASDAQ:DYN )
WALTHAM, Mass., Jan. 09, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. DYN, a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that John Cox, president and chief ...
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 09, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. ( Nasdaq: DYN ) , a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that John Cox, president ...
